<DOC>
	<DOCNO>NCT00968812</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy , safety , tolerability canagliflozin ( JNJ-28431754 ) compare glimepiride patient type 2 diabetes mellitus inadequate control despite treatment metformin .</brief_summary>
	<brief_title>CANagliflozin Treatment And Trial Analysis-Sulfonylurea ( CANTATA-SU ) SGLT2 Add-on Metformin Versus Glimepiride</brief_title>
	<detailed_description>Type 2 diabetes mellitus ( T2DM ) well recognize major public health problem present patient significant risk complication include heart disease , retinopathy , nephropathy , neuropathy . Various class orally administer antihyperglycemic agent develop treatment diabetes although individual agent may highly effective patient , still difficult maintain optimal glycemic control patient , thereby result high rate morbidity mortality diabetic population . This randomized , double-blind , active comparator-controlled , 3-arm , parallel-group , multicenter study demonstrate efficacy , safety , tolerability canagliflozin compare sulfonylurea ( glimepiride ) patient T2DM , 18 80 year age , inclusive , optimally control metformin monotherapy . The primary study hypothesis study drug non-inferior glimepiride assess change hemoglobin A1c ( HbA1c ) baseline . The patient receive capsule take mouth canagliflozin ( either 100 300 mg ) , glimepiride start dosage 1 mg , increase maximum dose 6 8 mg daily total duration 104 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Patients must diagnosis type 2 diabetes Body mass index ( BMI ) &gt; =22 &lt; =45 kg/m2 , screen Patients must take stable dosage metformin monotherapy screen Patients must HbA1c &gt; =7 % &lt; =9.5 % Week 2 Patients must fast plasma glucose ( FPG ) &lt; =270 mg/dL ( 15 mmol/L ) Week 2 Patients prior exposure know contraindication suspect hypersensitivity JNJ28431754 , glimepiride , metformin History diabetic ketoacidosis type 1 diabetes mellitus History pancreas betacell transplantation History active proliferative diabetic retinopathy History hereditary glucosegalactose malabsorption primary renal glucosuria Renal disease require treatment immunosuppressive therapy within past 12 month screen history dialysis renal transplant Taken thiazolidinedione therapy past 16 week screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Metformin</keyword>
	<keyword>Glimepiride</keyword>
	<keyword>Hemoglobin A1c</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Canagliflozin</keyword>
</DOC>